Zhejiang Hisun Pharmaceutical Co., Ltd. Class ASSE: 600267

"Zhejiang Hisun Pharmaceutical Co., Ltd."Announcement on the U.S. FDA Approval of Fludarabine Phosphate Injection of the Wholly-owned Subsidiary

· Issued by Zhejiang Hisun Pharmaceutical Co., Ltd. Class A via Shanghai Stock Exchange
Announcement on the U.S. FDA Approval of Fludarabine Phosphate Injection of the Wholly-owned Subsidiary

The abstract is for reference only. Please refer to the full text of the announcement on the very day.

Link of Full Text for Reference:
View Attachment

Company analysis

Earlier from Zhejiang Hisun Pharmaceutical Co., Ltd. Class A

All Zhejiang Hisun Pharmaceutical Co., Ltd. Class A news releases